Brolucizumab-related intraocular inflammation in Japanese patients with age-related macular degeneration: a short-term multicenter study.
作者信息
Maruko Ichiro, Okada Annabelle A, Iida Tomohiro, Hasegawa Taiji, Izumi Takahiko, Kawai Moeko, Maruko Ruka, Nakayama Makiko, Yamamoto Akiko, Koizumi Hideki, Tamashiro Tamaki, Terao Nobuhiro, Wakugawa Sorako, Mori Ryusaburo, Onoe Hajime, Tanaka Koji, Wakatsuki Yu, Itagaki Kanako, Kasai Akihito, Ogasawara Masashi, Sekiryu Tetsuju, Shintake Hiroaki, Sugano Yukinori
机构信息
Department of Ophthalmology, Tokyo Women's Medical University School of Medicine, Tokyo, Japan.
Department of Ophthalmology, Kyorin University School of Medicine, Tokyo, Japan.
出版信息
Graefes Arch Clin Exp Ophthalmol. 2021 Sep;259(9):2857-2859. doi: 10.1007/s00417-021-05136-w. Epub 2021 Mar 15.
Abstract
摘要
相似文献
1
Brolucizumab-related intraocular inflammation in Japanese patients with age-related macular degeneration: a short-term multicenter study.日本年龄相关性黄斑变性患者中与布罗鲁单抗相关的眼内炎症：一项短期多中心研究。
Graefes Arch Clin Exp Ophthalmol. 2021 Sep;259(9):2857-2859. doi: 10.1007/s00417-021-05136-w. Epub 2021 Mar 15.
2
[Bilateral occlusive vasculitis after intravitreal injection of brolucizumab in neovascular age-related macular degeneration].[玻璃体内注射布罗芦izumab治疗新生血管性年龄相关性黄斑变性后双侧闭塞性血管炎]
Ophthalmologe. 2022 Jan;119(1):75-78. doi: 10.1007/s00347-021-01323-6. Epub 2021 Feb 11.
3
Risk of Inflammation, Retinal Vasculitis, and Retinal Occlusion-Related Events with Brolucizumab: Post Hoc Review of HAWK and HARRIER.Brolucizumab 相关炎症、视网膜血管炎和视网膜阻塞相关事件的风险：HAWK 和 HARRIER 的事后回顾。
Ophthalmology. 2021 Jul;128(7):1050-1059. doi: 10.1016/j.ophtha.2020.11.011. Epub 2020 Nov 15.
4
Short-term outcomes of intravitreal brolucizumab for treatment-naïve neovascular age-related macular degeneration with type 1 choroidal neovascularization including polypoidal choroidal vasculopathy.初治 1 型脉络膜新生血管包括息肉样脉络膜血管病变的年龄相关性黄斑变性患者玻璃体腔内注射布罗利尤单抗的短期疗效。
Sci Rep. 2021 Mar 24;11(1):6759. doi: 10.1038/s41598-021-86014-7.
5
Risk factors for emerging intraocular inflammation after intravitreal brolucizumab injection for age-related macular degeneration.年龄相关性黄斑变性患者玻璃体内注射布罗利珠单抗后新发眼内炎症的危险因素。
PLoS One. 2021 Dec 6;16(12):e0259879. doi: 10.1371/journal.pone.0259879. eCollection 2021.
6
Brolucizumab: A Newly Developed Anti-VEGF Molecule for the Treatment of Neovascular Age-Related Macular Degeneration.Brolucizumab：一种新型抗 VEGF 分子，用于治疗新生血管性年龄相关性黄斑变性。
Ophthalmologica. 2021;244(2):93-101. doi: 10.1159/000513048. Epub 2020 Nov 16.
7
Brolucizumab as treatment of wet age-related maculopathy.Brolucizumab 治疗湿性年龄相关性黄斑病变。
Drugs Today (Barc). 2020 Nov;56(11):699-704. doi: 10.1358/dot.2020.56.11.3199812.
8
Brolucizumab: First Approval.布罗鲁单抗：首次批准。
Drugs. 2019 Dec;79(18):1997-2000. doi: 10.1007/s40265-019-01231-9.
9
Brolucizumab and fluid in neovascular age-related macular degeneration (n-AMD).布罗鲁单抗与新生血管性年龄相关性黄斑变性（n-AMD）中的积液
Eye (Lond). 2020 Aug;34(8):1310-1312. doi: 10.1038/s41433-020-0831-2. Epub 2020 Mar 4.
10
HAWK and HARRIER: Phase 3, Multicenter, Randomized, Double-Masked Trials of Brolucizumab for Neovascular Age-Related Macular Degeneration.HAWK 和 HARRIER：贝鲁珠单抗治疗新生血管性年龄相关性黄斑变性的 3 期、多中心、随机、双盲试验。
Ophthalmology. 2020 Jan;127(1):72-84. doi: 10.1016/j.ophtha.2019.04.017. Epub 2019 Apr 12.
引用本文的文献
1
Consensus of Expert Recommendations for the Safe Administration of Brolucizumab in Neovascular Age-related Macular Degeneration.雷珠单抗在新生血管性年龄相关性黄斑变性中安全应用的专家推荐共识
Korean J Ophthalmol. 2025 Aug;39(4):362-368. doi: 10.3341/kjo.2025.0010. Epub 2025 Aug 5.
2
Recurrence of Intraocular Inflammation Following an Aflibercept 8-mg Injection in Eyes With a History of Intraocular Inflammation From Faricimab: A Case Report.在有法西单抗所致眼内炎症病史的眼中注射8毫克阿柏西普后眼内炎症复发：一例报告
Cureus. 2025 Jun 16;17(6):e86113. doi: 10.7759/cureus.86113. eCollection 2025 Jun.
3
Usage of brolucizumab as treatment for wet age-related macular degeneration (AMD) and polypoidal choroidal vasculopathy (PCV): A narrative review.布罗鲁单抗用于湿性年龄相关性黄斑变性（AMD）和息肉状脉络膜血管病变（PCV）治疗的叙述性综述。
Medicine (Baltimore). 2025 Jun 6;104(23):e42666. doi: 10.1097/MD.0000000000042666.
4
Gender and ethnic diversity in randomised clinical trials in age-related macular degeneration and diabetic macular oedema.年龄相关性黄斑变性和糖尿病性黄斑水肿随机临床试验中的性别和种族多样性
Eye (Lond). 2025 May;39(7):1249-1253. doi: 10.1038/s41433-025-03595-7. Epub 2025 Feb 20.
5
Efficacy and safety of brolucizumab every 6 weeks induction therapy for neovascular age-related macular degeneration.每6周一次布罗珠单抗诱导疗法治疗新生血管性年龄相关性黄斑变性的疗效与安全性
Sci Rep. 2025 Feb 17;15(1):5705. doi: 10.1038/s41598-025-89638-1.
6
Intraocular inflammation after intravitreal injection of aflibercept 8 mg for treatment-refractory neovascular age-related macular degeneration: a case report.玻璃体内注射8毫克阿柏西普治疗难治性新生血管性年龄相关性黄斑变性后的眼内炎症：一例报告
BMC Ophthalmol. 2025 Jan 23;25(1):42. doi: 10.1186/s12886-024-03827-6.
7
Brolucizumab-associated intraocular inflammation in Indian patients by VRSI study group.由 VRSI 研究小组报告的印度患者中与 brolucizumab 相关的眼内炎症。
Indian J Ophthalmol. 2024 Aug 1;72(8):1156-1161. doi: 10.4103/IJO.IJO_2973_23. Epub 2024 Jul 29.
8
Switching from a Fixed Monthly Aflibercept Regimen to Bi-Monthly Brolucizumab in Refractory Cases of Neovascular Age-Related Macular Degeneration.在新生血管性年龄相关性黄斑变性难治性病例中，从每月一次的阿柏西普固定方案转换为每两个月一次的布罗芦izumab治疗。
J Clin Med. 2024 Jun 12;13(12):3434. doi: 10.3390/jcm13123434.
9
Safety and Effectiveness of Intravitreal Brolucizumab Injection in Combination With Sub-Tenon's Capsule Triamcinolone Acetonide Injection for Polypoidal Choroidal Vasculopathy During the Loading Phase.玻璃体内注射布罗芦izumab联合球后注射曲安奈德在息肉状脉络膜血管病变负荷期的安全性和有效性
Cureus. 2024 May 1;16(5):e59481. doi: 10.7759/cureus.59481. eCollection 2024 May.
10
Visual outcomes of intraocular inflammation after brolucizumab injection in Japanese patients with neovascular age-related macular degeneration.日本新生血管性年龄相关性黄斑变性患者接受 brolucizumab 注射后的眼内炎症的视觉结果。
PLoS One. 2024 Apr 18;19(4):e0302295. doi: 10.1371/journal.pone.0302295. eCollection 2024.
本文引用的文献
1
Risk of Inflammation, Retinal Vasculitis, and Retinal Occlusion-Related Events with Brolucizumab: Post Hoc Review of HAWK and HARRIER.Brolucizumab 相关炎症、视网膜血管炎和视网膜阻塞相关事件的风险：HAWK 和 HARRIER 的事后回顾。
Ophthalmology. 2021 Jul;128(7):1050-1059. doi: 10.1016/j.ophtha.2020.11.011. Epub 2020 Nov 15.
2
HAWK and HARRIER: Ninety-Six-Week Outcomes from the Phase 3 Trials of Brolucizumab for Neovascular Age-Related Macular Degeneration.HAWK和HARRIER：布罗鲁单抗治疗新生血管性年龄相关性黄斑变性3期试验的96周结果
Ophthalmology. 2021 Jan;128(1):89-99. doi: 10.1016/j.ophtha.2020.06.028. Epub 2020 Jun 20.
3
Retinal Vasculitis and Intraocular Inflammation after Intravitreal Injection of Brolucizumab.眼内注射布罗鲁单抗后视网膜血管炎和眼内炎症。
Ophthalmology. 2020 Oct;127(10):1345-1359. doi: 10.1016/j.ophtha.2020.04.017. Epub 2020 Apr 25.
Zotero 插件